Loading...
Loading...
ACLX| Name | Value |
|---|---|
| Revenues | 39.3M |
| Cost of Revenue | 0.8M |
| Gross Profit | 38.4M |
| Operating Expense | 54.2M |
| Operating I/L | -15.8M |
| Other Income/Expense | 8.6M |
| Interest Income | 9.2M |
| Pretax | -7.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -7.2M |
Arcellx, Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapies for cancer and other incurable diseases. The company's lead product candidate, CART-ddBCMA, is in phase 1 clinical trial for treating relapsed or refractory multiple myeloma. Additionally, Arcellx is developing ACLX-001, an immunotherapeutic combination targeting BCMA for the treatment of multiple myeloma, as well as ACLX-002 and ACLX-003 for r/r acute myeloid leukemia and myelodysplastic syndrome. The company also has solid tumor programs in its pipeline.
